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at www.jvascsurg.org.INVITED COMMENTARYLewis B. Schwartz, MD, Chicago, IllThe purpose of this randomized, double-blind, placebo-
controlled clinical trial was to test the hypothesis that topically
applied human pancreatic elastase would assist maturation and
extend the patency and usefulness of dialysis-access arteriovenous
ﬁstulas (AVFs). The authors and entrepreneurs are to be congrat-
ulated for their novel and ambitious approach to the difﬁcult prob-
lem of hemodialysis access, as well as for their revealing and
aspirational trial. Dependable maturation of AVFs remains a signif-
icant clinical challenge, and to date, there are no available chemical
strategies designed to improve outﬂow vein remodeling. Should
this strategy ultimately prove efﬁcacious, it would represent a sig-
niﬁcant advance in a challenging ﬁeld of medicine.
Unfortunately, the investigators overestimated the potential
beneﬁt of their therapy, because their prespeciﬁed primary end point
of a 30% absolute improvement in 1-year primary patency was not
achieved. The negative trial results will certainly present regulatory
challenges, and further study will undoubtedly be required to secure
approval. However, because the primary patency of the control,low-dose, and high-dose groups was 45%, 54%, and 53%, respec-
tively, a positive effect of the drug appeared to be demonstrated.
Thus, the study was not a failure; it was simply underpowered to
demonstrate the 10% effect size of the experimental intervention.
Certainly, a simple maneuver, such as intraoperative elastase
application, would be clinically useful and widely applied if it reli-
ably provided a 10% increase in patency. Moreover, there were
positive trends favoring the experimental groups in all metrics,
most notably for primary patency in radiocephalic AVFs and in
“maturation-by-3-months” in all groups. Improvements in the
number and rapidity by which radiocephalic AVFs matured into
useful conduits would be welcome, indeed.
The concept that topically applied human pancreatic elastase
can assist the maturation of outﬂow veins in dialysis access AVFs
has been demonstrated. This bold trial should be viewed as a
mechanistic and clinical success and this development group
should muster the will and ﬁnancial resources to continue their
important line of research.
